Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.32 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364355 | 0.78 | NUDT1 (0.39) | LMNAKMT2AMEN1NUDT1BACE1 | |
| SCHEMBL3181813 | 0.76 | NUDT1 (0.40) | KMT2AMEN1NUDT1BACE1HSP90AA1 | |
| SCHEMBL278769 | 0.76 | NUDT1 (0.40) | KMT2AMEN1NUDT1BACE1HSP90AA1 | |
| SCHEMBL899712 | 0.76 | MEN1 (0.38) | KMT2AMEN1NUDT1BACE1HSP90AA1 | |
| SCHEMBL30060700 | 0.76 | NUDT1 (0.37) | LMNAKMT2AMEN1NUDT1BACE1 | |
| SCHEMBL278543 | 0.76 | NUDT1 (0.37) | LMNAKMT2AMEN1NUDT1BACE1 | |
| SCHEMBL29623069 | 0.76 | NUDT1 (0.37) | LMNAKMT2AMEN1NUDT1BACE1 | |
| SCHEMBL15253181 | 0.75 | NUDT1 (0.39) | KMT2AMEN1NUDT1BACE1HSP90AA1 | |
| SCHEMBL8512087 | 0.74 | NPC1 (0.39) | NPC1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL3184220 | 0.73 | NUDT1 (0.40) | NUDT1BACE1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012044719-A1 | NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC | PROMERUS LLC (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | NBAS, PHB2, BDNF | NPC1 4802/4885HPGD 2012/4885LMNA 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.